$2.42 Billion is the total value of Rock Springs Capital Management LP's 131 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 39.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| UNH | Sell | UNITEDHEALTH GROUP INC | $74,814,000 | -56.9% | 300,000 | -49.2% | 3.09% | -43.7% |
| HUM | Sell | HUMANA INC | $49,458,000 | -27.1% | 157,500 | -14.9% | 2.04% | -4.5% |
| FTSV | Sell | FORTY SEVEN INC | $42,691,000 | +141.0% | 447,400 | -0.6% | 1.76% | +215.2% |
| PEN | Sell | PENUMBRA INC | $36,299,000 | -8.9% | 225,000 | -7.2% | 1.50% | +19.2% |
| BSX | Sell | BOSTON SCIENTIFIC CORP | $35,893,000 | -33.9% | 1,100,000 | -8.3% | 1.48% | -13.5% |
| EPZM | Sell | EPIZYME INC | $30,322,000 | -39.9% | 1,955,000 | -4.6% | 1.25% | -21.3% |
| PCRX | Sell | PACIRA BIOSCIENCES | $30,177,000 | -42.1% | 900,000 | -21.7% | 1.25% | -24.2% |
| VRTX | Sell | VERTEX PHARMACEUTICALS INC | $29,744,000 | -33.1% | 125,000 | -38.4% | 1.23% | -12.4% |
| COLL | Sell | COLLEGIUM PHARMACEUTICAL INC | $19,188,000 | -40.8% | 1,175,000 | -25.4% | 0.79% | -22.6% |
| MIRM | Sell | MIRUM PHARMACEUTICALS INC | $17,402,000 | -43.0% | 1,243,000 | -0.2% | 0.72% | -25.4% |
| APRE | Sell | APREA THERAPEUTICS INC | $17,380,000 | -47.7% | 500,000 | -30.9% | 0.72% | -31.5% |
| MDGL | Sell | MADRIGAL PHARMACEUTICALS INC | $16,690,000 | -26.8% | 250,000 | -0.1% | 0.69% | -4.2% |
| ACHC | Sell | ACADIA HEALTHCARE COMPANY IN | $16,515,000 | -49.0% | 900,000 | -7.7% | 0.68% | -33.2% |
| NVTA | Sell | INVITAE CORP | $15,721,000 | -18.8% | 1,150,000 | -4.2% | 0.65% | +6.2% |
| DCPH | Sell | DECIPHERA PHARMACEUTICALS IN | $13,792,000 | -47.5% | 335,000 | -20.6% | 0.57% | -31.3% |
| JNJ | Sell | JOHNSON & JOHNSON | $13,769,000 | -83.1% | 105,000 | -81.2% | 0.57% | -77.9% |
| RDUS | Sell | RADIUS HEALTH INC | $12,675,000 | -37.1% | 975,000 | -2.5% | 0.52% | -17.7% |
| WST | Sell | WEST PHARMACEUTICAL SVSC INC | $10,810,000 | -52.8% | 71,000 | -53.4% | 0.45% | -38.3% |
| TBIO | Sell | TRANSLATE BIO INC | $8,225,000 | +6.4% | 825,000 | -13.2% | 0.34% | +39.3% |
| XENT | Sell | INTERSECT ENT INC | $5,925,000 | -70.3% | 500,000 | -37.5% | 0.24% | -61.0% |
| TMO | Sell | THERMO FISHER SCIENTIFIC INC | $4,963,000 | -81.1% | 17,500 | -78.4% | 0.20% | -75.3% |
| AXNX | Sell | AXONICS MODULATION TECHNOLOG | $3,176,000 | -89.6% | 125,000 | -88.6% | 0.13% | -86.4% |
| Sell | NABRIVA THERAPEUTICS PLC | $604,000 | -78.2% | 1,050,000 | -50.0% | 0.02% | -71.6% | |
| PFE | Exit | PFIZER INC | $0 | – | -10,400 | -100.0% | -0.01% | – |
| CRVS | Exit | CORVUS PHARMACEUTICALS INC | $0 | – | -150,000 | -100.0% | -0.03% | – |
| Exit | DERMIRA INCnote 3.000% 5/1 | $0 | – | -1,000,000 | -100.0% | -0.03% | – | |
| BLUE | Exit | BLUEBIRD BIO INC | $0 | – | -35,000 | -100.0% | -0.10% | – |
| RTIX | Exit | RTI SURGICAL HOLDINGS INC | $0 | – | -1,950,000 | -100.0% | -0.17% | – |
| ICPT | Exit | INTERCEPT PHARMACEUTICALS IN | $0 | – | -54,400 | -100.0% | -0.21% | – |
| Exit | MEDICINES COnote 2.750% 7/1 | $0 | – | -5,000,000 | -100.0% | -0.28% | – | |
| BMY | Exit | BRISTOL MYERS SQUIBB CO | $0 | – | -150,000 | -100.0% | -0.30% | – |
| DERM | Exit | DERMIRA INC | $0 | – | -650,000 | -100.0% | -0.31% | – |
| INSM | Exit | INSMED INC | $0 | – | -800,000 | -100.0% | -0.60% | – |
| ACHN | Exit | ACHILLION PHARMACEUTICALS IN | $0 | – | -3,685,000 | -100.0% | -0.70% | – |
| BOLD | Exit | AUDENTES THERAPEUTICS INC | $0 | – | -410,000 | -100.0% | -0.78% | – |
| MDCO | Exit | MEDICINES CO | $0 | – | -307,699 | -100.0% | -0.83% | – |
| RARX | Exit | RA PHARMACEUTICALS INC | $0 | – | -750,000 | -100.0% | -1.11% | – |
| WCG | Exit | WELLCARE HEALTH PLANS INC | $0 | – | -320,500 | -100.0% | -3.34% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTUITIVE SURGICAL INC | 40 | Q3 2023 | 3.4% |
| NEUROCRINE BIOSCIENCES INC | 39 | Q3 2023 | 4.8% |
| PACIRA PHARMACEUTICALS INC | 39 | Q3 2023 | 2.6% |
| ULTRAGENYX PHARMACEUTICAL IN | 39 | Q3 2023 | 1.9% |
| ACADIA HEALTHCARE COMPANY IN | 38 | Q3 2023 | 4.4% |
| ASCENDIS PHARMA A/S | 35 | Q3 2023 | 1.3% |
| INVITAE CORP | 35 | Q3 2023 | 1.8% |
| BIOMARIN PHARMACEUTICAL INC | 35 | Q3 2023 | 1.3% |
| MACROGENICS INC | 35 | Q3 2023 | 0.5% |
| COLLEGIUM PHARMACEUTICAL INC | 34 | Q3 2023 | 2.1% |
View Rock Springs Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 3,413,906 | 5.6% |
| Compass Therapeutics, Inc. | February 14, 2023 | 5,333,188 | 4.2% |
| Mirum Pharmaceuticals, Inc. | February 14, 2023 | 1,795,733 | 4.9% |
| PhaseBio Pharmaceuticals IncSold out | February 14, 2023 | 0 | 0.0% |
| Sierra Oncology, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ARDELYX, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| CHIASMA, INCSold out | February 15, 2022 | 0 | 0.0% |
| FIVE PRIME THERAPEUTICS, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| F-star Therapeutics, Inc. | February 15, 2022 | 751,889 | 3.6% |
| Protara Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
View Rock Springs Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-01 |
| SC 13G/A | 2024-04-05 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Rock Springs Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.